TY - JOUR
T1 - Effect on post-operative pulmonary complications frequency of high flow nasal oxygen versus standard oxygen therapy in patients undergoing esophagectomy for cancer
T2 - study protocol for a randomized controlled trial—OSSIGENA study
AU - Ossigena Study Group
AU - Deana, Cristian
AU - Vecchiato, Massimo
AU - Azzolina, Danila
AU - Turi, Stefano
AU - Boscolo, Annalisa
AU - Pistollato, Elisa
AU - Skurzak, Stefano
AU - Amici, Ombretta
AU - Priolo, Simone
AU - Tonini, Simone
AU - Foti, Lorenzo Santo
AU - Taddei, Erika
AU - Aceto, Paola
AU - Martino, Antonio
AU - Ziccarelli, Antonio
AU - Cereser, Lorenzo
AU - Andreutti, Simonetta
AU - De Carlo, Stefano
AU - Lirussi, Kevin
AU - Barbariol, Federico
AU - Cammarota, Gianmaria
AU - Polati, Enrico
AU - Forfori, Francesco
AU - Corradi, Francesco
AU - Patruno, Vincenzo
AU - Navalesi, Paolo
AU - Maggiore, Salvatore Maurizio
AU - Lucchese, Francesca
AU - Petri, Roberto
AU - Bassi, Flavio
AU - Romagnoli, Stefano
AU - Bignami, Elena Giovanna
AU - Vetrugno, Luigi
N1 - Publisher Copyright:
© Journal of Thoracic Disease. All rights reserved.
PY - 2024/8/31
Y1 - 2024/8/31
N2 - Background: Postoperative pulmonary complications (PPCs) remain a challenge after esophagectomy. Despite improvement in surgical and anesthesiological management, PPCs are reported in as many as 40% of patients. The main aim of this study is to investigate whether early application of high-flow nasal cannula (HFNC) after extubation will provide benefit in terms of reduced PPC frequency compared to standard oxygen therapy. Methods: Patients aged 18–85 years undergoing esophagectomy for cancer treatment with radical intent, excluding those with American Society of Anesthesiologists (ASA) score >3 and severe systemic comorbidity (cardiac, pulmonary, renal or hepatic disease) will be randomized at the end of surgery to receive HFNC or standard oxygen therapy (Venturi mask or nasal goggles) after early extubation (within 12 hours after the end of surgery) for 48 hours. The main postoperative goals are to obtain SpO2 ≥94% and adequate pain control. Oxygen therapy after 48 hours will be stopped unless the physician deems it necessary. In case of respiratory clinical worsening, patients will be supported with the most appropriate tool (noninvasive ventilation or invasive mechanical ventilation). Pulmonary [pneumonia, pleural effusion, pneumothorax, atelectasis, acute respiratory distress syndrome (ARDS), tracheo-bronchial injury, air leak, reintubation, and/or respiratory failure] complications will be recorded as main outcome. Secondary outcomes, including cardiovascular, surgical, renal and infective complications will also be recorded. The primary analysis will be carried out on 320 patients (160 per group) and performed on an intention-to-treat (ITT) basis, including all participants randomized into the treatment groups, regardless of protocol adherence. The primary outcome, the PPC rate, will be compared between the two treatment groups using a chi-square test for categorical data, or Fisher’s exact test will be used if the assumptions for the chi-square test are not met. Discussion: Recent evidence demonstrated that early application of HFNC improved the respiratory rate oxygenation index (ROX index) after esophagectomy but did not reduce PPCs. This randomized controlled multicenter trial aims to assess the potential effect of the application of HFNC versus standard oxygen over PPCs in patients undergoing esophagectomy.
AB - Background: Postoperative pulmonary complications (PPCs) remain a challenge after esophagectomy. Despite improvement in surgical and anesthesiological management, PPCs are reported in as many as 40% of patients. The main aim of this study is to investigate whether early application of high-flow nasal cannula (HFNC) after extubation will provide benefit in terms of reduced PPC frequency compared to standard oxygen therapy. Methods: Patients aged 18–85 years undergoing esophagectomy for cancer treatment with radical intent, excluding those with American Society of Anesthesiologists (ASA) score >3 and severe systemic comorbidity (cardiac, pulmonary, renal or hepatic disease) will be randomized at the end of surgery to receive HFNC or standard oxygen therapy (Venturi mask or nasal goggles) after early extubation (within 12 hours after the end of surgery) for 48 hours. The main postoperative goals are to obtain SpO2 ≥94% and adequate pain control. Oxygen therapy after 48 hours will be stopped unless the physician deems it necessary. In case of respiratory clinical worsening, patients will be supported with the most appropriate tool (noninvasive ventilation or invasive mechanical ventilation). Pulmonary [pneumonia, pleural effusion, pneumothorax, atelectasis, acute respiratory distress syndrome (ARDS), tracheo-bronchial injury, air leak, reintubation, and/or respiratory failure] complications will be recorded as main outcome. Secondary outcomes, including cardiovascular, surgical, renal and infective complications will also be recorded. The primary analysis will be carried out on 320 patients (160 per group) and performed on an intention-to-treat (ITT) basis, including all participants randomized into the treatment groups, regardless of protocol adherence. The primary outcome, the PPC rate, will be compared between the two treatment groups using a chi-square test for categorical data, or Fisher’s exact test will be used if the assumptions for the chi-square test are not met. Discussion: Recent evidence demonstrated that early application of HFNC improved the respiratory rate oxygenation index (ROX index) after esophagectomy but did not reduce PPCs. This randomized controlled multicenter trial aims to assess the potential effect of the application of HFNC versus standard oxygen over PPCs in patients undergoing esophagectomy.
KW - Esophagectomy
KW - high-flow nasal cannula (HFNC)
KW - outcome
KW - perioperative medicine
KW - postoperative pulmonary complications (PPCs)
UR - https://www.scopus.com/pages/publications/85202875464
U2 - 10.21037/jtd-24-575
DO - 10.21037/jtd-24-575
M3 - Article
SN - 2072-1439
VL - 16
SP - 5388
EP - 5398
JO - Journal of Thoracic Disease
JF - Journal of Thoracic Disease
IS - 8
ER -